Balance sheet looks good, new drugs promising - 5 drugs in phase 1 trials! By year end will have at LEAST 1 phase 3 indication for SG-110. 300 patents and 560 patent applications!
This stock is going to be the next PCYC.
Sentiment: Strong Buy
never heard this many analyst questions. wow, RBC, JMP, Edison Group and Oppenheimer won't let this conference call end. One big deal, now they are talking about "one or more" ph III's for SGI-110. this puppy might pay off one of my houses.